Please assess the completion status of the following clinical trial:

Trial Title: Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 25-75 years old.~* Gender: female~* Newly diagnosed HER2 positive breast cancer patients who are scheduled to receive doxorubicin followed by trastuzumab adjuvant therapy.~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2~* Preserved LV systolic function in which the left ventricular ejection fraction (LVEF)≥50%.~* Patients with normal renal and hematological functions.~* Alanine amino transferase (ALT ≤ 3 times ULN).~Exclusion Criteria:~* Pregnant or lactating females.~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) \> 2~* Patients with impaired LV systolic function in which the left ventricular ejection fraction (LVEF)\<50%.~* Patients with significant valvular heart disease, documented coronary artery disease, history of congestive heart failure or cardiomyopathy.~* Alanine amino transferase (ALT \> 3 times ULN).~* Patients already taking statins or other lipid lowering therapy.~* Patients with a known hypersensitivity to any of the used drugs.

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- control-group (Type: NO_INTERVENTION): This group will include 25 patients who will receive doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy.
- rosuvastatin-group (Type: ACTIVE_COMPARATOR): This group will include 25 patients who will receive doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy in addition to 20 mg of oral rosuvastatin 24 hours prior to the first cycle of chemotherapy and once daily for the rest of the follow-up period (6 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).